Bristol Myers Squibb has completed the acquisition of RayzeBio, a biotechnology company. The acquisition is part of Bristol Myers Squibb’s strategy to expand its portfolio of innovative therapies. By continuing to use our site, you agree to the use of cookies for analytics, advertising, and site improvement. To learn more about our cookie policy and settings, please refer to our Cookie Policy.
Source link
Bristol Myers Squibb concludes acquisition of RayzeBio
